Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 12, 2016
- Accepted in final form October 20, 2016
- First Published November 17, 2016.
Author Disclosures
- Anne-Katrin Pröbstel, MD,
- André Schaller, PhD,
- Johanna Lieb, MD,
- Juergen Hench, MD,
- Stephan Frank, MD,
- Peter Fuhr, MD,
- Ludwig Kappos, MD and
- Michael Sinnreich, MD, PhD
- Anne-Katrin Pröbstel, MD,
Dr. Pr?bstel has served on the scientific advisory board of Bayer.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Pr?bstel received research support from Genzyme.
NONE
Dr. Pr?bstel received research funding from University of Basel.
Dr. Pr?bstel received research funding from the Swiss National Science Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- André Schaller, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Novartis Foundation for medical-biological researchdiscussed your application nr. 16B130 ?Molecularcharacterisation of mitochondrial disorders?
NONE
NONE
NONE
NONE
NONE
NONE
- Johanna Lieb, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Juergen Hench, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephan Frank, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Fuhr, MD,
(1)General Electrics: Advisory Board (2)UCB: Advisory Board (3)Biogen: Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
30% Clinic for and research in Movement Disorders, University Hospital of Basel, Switzerland 50% Section of Clinical Neurophysiology (clinical application and Research), University Hospital of Basel, Switzerland 20% General Neurology and Administration, University Hospital of Basel, Switzerland
(1) Roche (2) AbbVie (3) General Electric (4) Biogen
NONE
(1) Swiss National Science Foundation
(1) Synapsis Foundation; principle investigator; 2009-2011 (2) Gossweiler Foundation; principle investigator; 2011- 2012 (3) Botnar Foundation; principle investigator; 2012-2015 (4) Parkinson Association Switzerland; principle investigator, 2010-2012 (5) Parkinson Association Switzerland; principle investigator, 2013-2014 (6) Mach-Gaensslen Foundation; principle investigator, 2012-2014 (7) Gottfried and Julia Bangerter-Rhyner Foundation; principle investigator, 2013-2014
NONE
NONE
NONE
NONE
NONE
NONE
- Ludwig Kappos, MD and
NONE
NONE
NONE
(1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology member of the Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Actelion, (2)Alkermes, (3)Almirall, (4)Bayer, (5)Biogen, (6)Excemed, (7)GeNeuro SA, (8)Genzyme, (9)Merck, (10)Mitsubishi Pharma, (11)Novartis, (12)Receptos, (13)Roche, (14)sanofi-aventis, (15)Santhera, (16)Teva, (17)Vianex
NONE
NONE
(1)the Swiss MS Society, (2)the Swiss National Research Foundation, (3)the European Union, (4)Roche Research Foundations
NONE
(1) license fees for Neurostatus products paid directly to University Hospital Basel
NONE
NONE
NONE
NONE
- Michael Sinnreich, MD, PhD
NONE
NONE
Institution received speaker honoraria from Novartis and Mepha for CME activities, which were used exclusively for research support.
Acta Myologica, Editorial board
A method for evaluating a candidate compound for treating Myotonic Dystrophy type 1 (DM1).
NONE
NONE
NONE
NONE
NONE
University Hospital Basel, Neurology Clinic and Neuromuscular Research, 100% effort, 2009 - present
Institution received research support from CSL Behring and Roche
Swiss National Science Foundation, grant number 31003A_146359, principal investigator
NONE
(1) Gebert-Ruef Foundation (2) Uniscientia Foundation (3) Neuromuscular Research Association Basel (4) Myosuisse
NONE
NONE
NONE
NONE
Novartis, 2014 - 2016 Roche, 2014 - 2015, March
NONE
- From the Neurologic Clinic and Policlinic (A.-K.P., P.F., L.K., M.S.), Departments of Medicine and Biomedicine; Division of Neuroradiology (J.L.), Department of Radiology; and Division of Neuropathology (J.H., S.F.), Department of Pathology, University Hospital Basel, University of Basel, Switzerland; Division of Human Genetics (A.S.), Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.
- Correspondence to Dr. Sinnreich: Michael.Sinnreich{at}usb.ch
Article usage
Letters: Rapid online correspondence
- Autonomic failure is central to MSA diagnosis
- Jeremy K Cutsforth-Gregory, Senior Associate Consultant Neurologist, Mayo Cliniccutsforthgregory.jeremy@mayo.edu
- Elizabeth A. Coon, Rochester, MN
Submitted January 13, 2017
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriersNora Weiduschat, Petra Kaufmann, Xiangling Mao et al.Neurology, January 29, 2014 -
Articles
The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarctK. Majamaa, J. Turkka, M. Kärppä et al.Neurology, November 01, 1997 -
Articles
Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotypeP. Kaufmann, K. Engelstad, Y. Wei et al.Neurology, November 16, 2011 -
Article
Intramyocellular lipid excess in the mitochondrial disorder MELASMRS determination at 7TSailaja Golla, Jimin Ren, Craig R. Malloy et al.Neurology: Genetics, May 25, 2017